



# HIGH ENROLL

**BUILDING SOLUTIONS FOR  
SITE ENROLLMENT**

# YOUR LEADERSHIP TEAM



**Dylan Steen MD MS**  
CEO/Founder



**Ginger Conway CNP**  
COO/Founder



**Cliff Browning**  
VP Sales/Development



**Matt Vorst**  
Chief Technical Officer

# LACK OF HEALTHCARE PROVIDER AWARENESS/ENGAGEMENT


## Background

Healthcare providers make decisions regarding every aspect of care.


## The Big, Hairy Problem

Vast majority of healthcare providers and patients are not aware nor able to easily engage in research.

## Healthcare Provider Engagement



# CHALLENGES FACED BY HEALTHCARE PROVIDERS




DERIVED FROM THOUSANDS OF USER INTERVIEWS CONDUCTED BY HIGH ENROLL

# PROVIDER AND RESEARCH TEAM PLATFORM

## Open Access Mobile App

*All internal/external healthcare providers-*  
Awareness, info, communication, and referral tool.



## Web-based Admin Portal

*Used by research managers and coordinators-*  
Create/manage all content easily.

/study/

Settings Studies Statistics Support

Dylan Steen  
Miami Cardiac & Vascular Institute

Search Studies

Category: All > - Select -

My Studies Only:

Add Study

**Complex AAA chEVAS Endovascular Repair for Complex AAA**  
ChEVAS System for endovascular repair of abdominal aortic aneurysms (AAA)  
Non-randomized study for the evaluation of the novel ChEVAS System for endovascular repair of paravisceral, juxtarenal, and pararenal abdominal aortic aneurysms (some infra-renal aneurysms will also be included). The anatomy of these aneurysms has previously presented difficulty for repair and avoidance of long-term complications.

**CONFIRM 2 Analysis of Coronary CTA and Outcomes**  
Association of coronary CT angiography findings with clinical outcomes over follow-up  
Open-label, observational registry designed to comprehensively evaluate the relationship of coronary computed tomographic angiography [CCTA] findings (including coronary, non-coronary cardiac, non-cardiac vascular, and clinical variables) to future clinical outcomes in patients undergoing clinically indicated CCTA

**PACE Trial Mitigating Critical Limb Ischemia**  
Treating limb ischemia using a cell-based therapy when unsuitable for revascularization  
Randomized, double-blind, placebo-controlled, study to evaluate intramuscular injections of PLX-PAD for the treatment of patients with critical limb ischemia (CLI) with minor tissue loss who are unsuitable for revascularization


**RLF-100-01 Aviptadil in Critical COVID-19**  
Aviptadil, a synthetic vasoactive intestinal peptide, to reduce pulmonary complications  
Randomized, double-blind trial of escalating doses of aviptadil in critical COVID-19

**BMAD HF Wearable System to Improve HF Care**  
Home-based monitoring for patients with recent heart failure hospitalization  
Observational study of patients hospitalized for acute decompensated heart failure (HF) or presenting to an outpatient clinic within 10 days post-hospital discharge for heart failure. The wearable Microcor device aims to improve ambulatory heart failure management

# HEALTHCARE PROVIDER MOBILE APP


## Features:

- No login/password to get started
- Personalization to each user's interests
- Easy searchability for studies
- Curated content for each study (e.g. facilitate provider "pitches")
- One-touch communication to an available research coordinator
- Easy-to-share capabilities
- Unlimited use at site and all its neighboring institutions
- Comprehensive/updated portfolio of all active, enrolling studies
- Push notifications for new studies or study information updates
- Performance data are provided for improvement
- IRB approval not required for provider-facing content
- Available for IOS and Android phones




# INCREASING PATIENT AND PUBLIC AWARENESS/ENGAGEMENT

High Enroll's web-based platform also provides research teams a simple and fast way to create, edit, and disseminate high-quality, trackable content to patient and the broader public.



Patient Enroll PWA



Paper Materials (Tearpads/Posters)



QR Codes



Facebook / Digital Media



API included so that your research site's public-facing website(s) are automatically updated from High Enroll!

# SUMMARY

## Value Proposition:

- “Frictionless” experience for users
- Broadly engage providers/patients
- Single source of “truth” for all marketing
- Increase offsite, external collaborations
- Increase annual revenues

Try the app for yourself



**University of CINCINNATI CANCER CENTER**  
University of Cincinnati • UC Health • Cincinnati Children's

Cancer Clinical Trials Newsletter | November 2022

**Featured Clinical Trial**

**A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral irreversible menin inhibitor, in adult patients with acute leukemia including those with an MLL/KMT2A gene rearrangement or NPM1 mutation**

**BF-MNN-101 | IRB 2022-0201**  
PI: Emily Curran, MD  
Coordinator: Nadia Osman, [osmann@ucmail.uc.edu](mailto:osmann@ucmail.uc.edu)

This is a Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with acute myeloid leukemia, acute lymphocytic leukemia with KMT2A/MLL1r, NPM1 and other mutations.

**Newly Open to Accrual**

2021-1306 IRB 2022-0420	<b>A Phase 1 Open-Label Study of the Safety, Tolerability and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer (INKT; agent-797) as a Single Agent and in Combination With Approved Immune Checkpoint Inhibitors in Patients With Relapsed/Refractory Solid Tumors</b> PI: Trisha Wise-Draper, MD, PhD Coordinator: Kayla Webb, <a href="mailto:webb2ka@ucmail.uc.edu">webb2ka@ucmail.uc.edu</a>
PRECISIONPROMISE IRB 2022-0268	<b>PRECISION PROMISE PLATFORM TRIAL FOR METASTATIC PANCREATIC CANCER</b> PI: Davendra Sohal, MD, MPH Coordinator: Jasmine Parker, <a href="mailto:parkerje@ucmail.uc.edu">parkerje@ucmail.uc.edu</a>
MK3475-C93 IRB 2021-0958	<b>A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma</b> PI: Caroline Billingsley, MD Coordinator: Margan Harris, <a href="mailto:harris3mm@ucmail.uc.edu">harris3mm@ucmail.uc.edu</a>

Download on the App Store | GET IT ON Google Play

**HIGH ENROLL**

The High Enroll app provides an easy way to stay up-to-date on clinical trials. See new studies and easily connect with the research coordinator.  
[Download the app](#)